

Clearside Biomedical, Inc. Announces Purchase of iScience Patent Portfolio for Suprachoroidal Space Drug Delivery

April 22, 2015 12:32 AM ET

Alpharetta, GA (April 22, 2015) – Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the purchase and acquisition of iScience Interventional Corporation's patent portfolio covering drug delivery to the suprachoroidal space (SCS). The iScience SCS patent portfolio includes United States and international patents and patent applications. The purchased portfolio claims methods of reaching the SCS using guided surgical delivery and devices to accomplish the same, and includes some first patent filings demonstrating delivery of therapeutic agents and formulation technology to the SCS.

The inclusion of the iScience patent portfolio complements Clearside's own intellectual property portfolio which protects its drug candidates, microinjector and non-surgical drug administration into the SCS. The strategic combination of both portfolios strengthens Clearside's intellectual property portfolio so that it protects both surgical and non-surgical SCS drug delivery technologies in the United States and other developed drug and medical technology markets.

Drug delivery to the SCS using Clearside's proprietary microinjector is believed to provide a number of potential benefits, including improved bioavailability at the site of the disease and faster onset of therapeutic effect, similar drug efficacy profiles with lower drug concentrations, improved treatment duration resulting in less frequent injections and enhanced safety profiles.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside's product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema. Visit www.clearsidebio.com for more information.

Contact

Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005
charlie.deignan@clearsidebio.com